Merck & Co. Inc. (MRK)

76.06
NYSE : Health Technology
Prev Close 74.84
Day Low/High 74.55 / 76.25
52 Wk Low/High 52.83 / 76.25
Avg Volume 10.03M
Exchange NYSE
Shares Outstanding 2.60B
Market Cap 194.61B
EPS 0.90
P/E Ratio 59.87
Div & Yield 2.20 (2.57%)

Latest News

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

There is clear divergence between the best and the worst performers in each sector this earnings season.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

A Bullish Options Play on Allergan

A Bullish Options Play on Allergan

Buyout rumors aside, AGN is a name I still find attractive.

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck is vey overbought on a number of time frames.

Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval

Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval

Merck shares retreat as regulatory approval ramps up speculation.

Jim Cramer: This Is a Rotation, Not a Recession

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.

Family Offices Inject Capital Into Budding Cannabis Industry

Family Offices Inject Capital Into Budding Cannabis Industry

Family offices, which manage billions of dollars and have much fewer restrictions on how they deploy capital, have been wading into the cannabis space with increasing frequency.

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

These blue chips pay shareholders handsomely in the form of dividends and share buybacks.

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.

Galmed Soars on Encouraging Trial Results

Markets have perked up just a tad across the board since our last update. As mentioned in an earlier post, Galmed Pharmaceuticals is the second small-cap NASH (nonalcoholic steatohepatitis) play that has soared over the past week. The shares are up ...

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

I continue to see these names as bargains in the biotech and biopharma space.

Small Cap Biotech Bargains

Small Cap Biotech Bargains

Here are 2 small caps I continue to see as bargains in this space.

Jim Cramer: Tech Can't Do it All Alone

Jim Cramer: Tech Can't Do it All Alone

Tech and retail gains aren't enough to lead markets to new highs.

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

These names are moving up or down in a big way ahead of releasing drug-trial results.

4 Names to Buy in a Refreshed Biotech Space

4 Names to Buy in a Refreshed Biotech Space

After a strong week for the biotech sector, these names have potential catalysts to move shares.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Don't Throw in the Towel on Merck After Earnings Selloff

Don't Throw in the Towel on Merck After Earnings Selloff

Let's take a look at the charts and indicators to see what may lie ahead for this drug maker.

Are Apple's Best Days in the Past?: Market Recon

Are Apple's Best Days in the Past?: Market Recon

I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.

Intermediate Trade: Merck

Intermediate Trade: Merck

2018 should be the beginning of Merck's earnings return to growth.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Watch for these upstart names to topple some big-caps going forward.

Buyers of Merck's Stock Have Become More Bullish in the Past 4 Months

Buyers of Merck's Stock Have Become More Bullish in the Past 4 Months

Let's review the charts and indicators to see where this move may carry in the weeks ahead.